TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative have launched a Phase 2a dose-expansion trial of TTX-MC138, an RNA-targeting therapeutic aimed at preventing metastatic recurrence in colorectal cancer patients who are ctDNA-positive after standard curative treatment. The trial is part of the PRE-I-SPY platform and will enroll up to 45 patients in early 2026, led by Dr. Paula Pohlmann at MD Anderson Cancer Center.

Why ctDNA-positive patients represent a new front in recurrence prevention

The trial’s focus on patients who are pathologically disease-free but remain ctDNA-positive targets a molecularly defined risk group that has been notoriously difficult to treat. In colorectal cancer, these patients often relapse despite appearing clinically cured. Circulating tumor DNA has become one of the most promising tools for detecting minimal residual disease and predicting recurrence risk far earlier than imaging or clinical symptoms.

Unlike conventional post-treatment surveillance approaches, this study takes a proactive stance by attempting to eradicate micrometastatic disease before it manifests clinically. This model reflects a growing emphasis on molecular minimalism—focusing on eliminating molecularly visible, but radiographically invisible disease. Clinicians following this space point out that while ctDNA detection is increasingly used to stratify patient risk, few therapies have been validated specifically for ctDNA-positive settings, making this trial one of the more closely watched initiatives in the space.

How TTX-MC138 is positioned as a first-in-class microRNA therapeutic

TTX-MC138 is engineered to inhibit microRNA-10b, or miR-10b, a regulatory RNA molecule widely implicated in cancer metastasis. Elevated miR-10b expression has been linked to poor prognosis and aggressive disease in multiple solid tumors, including colorectal cancer. TransCode Therapeutics is one of the few companies to pursue direct inhibition of this microRNA as a therapeutic strategy.

Unlike conventional chemotherapeutic or targeted agents that directly kill tumor cells or block oncogenic proteins, TTX-MC138 is designed to block the molecular triggers of metastasis before they cascade into macroscopic disease. The drug completed a first-in-human Phase 1a trial with a clean safety profile and what the company described as durable anti-tumor activity, supporting dose advancement into this new Phase 2a setting.

This approach represents a paradigm shift in how metastasis is managed. Instead of waiting for detectable spread, TTX-MC138 seeks to intervene at the molecular initiation point of metastasis. For clinicians focused on the biology of disease progression, this trial offers a unique test case for whether the inhibition of a non-coding RNA can halt or delay relapse in high-risk patients who otherwise lack viable treatment options.

Why the PRE-I-SPY platform offers more than just operational speed

The inclusion of TTX-MC138 in Quantum Leap’s PRE-I-SPY platform could provide critical acceleration, not just for enrollment and data collection, but for regulatory engagement. The PRE-I-SPY model, built as an extension of the better-known I-SPY family of adaptive platform trials, is specifically tailored to test early-phase therapies in biomarker-defined populations.

The platform’s infrastructure allows for continuous data analysis, efficient trial design adjustments, and access to a collaborative network of academic and clinical sites. From a regulatory and translational standpoint, participation in a platform trial increases credibility and statistical power, especially for novel agents like RNA therapeutics that may face skepticism in traditional trial settings.

Platform sponsors suggest the design also allows for better patient stratification and integration of real-time ctDNA monitoring, which could serve as both a predictive and pharmacodynamic biomarker in this trial. Regulatory strategists watching the trial suggest that successful readouts could streamline the pathway to Breakthrough Therapy Designation or similar expedited programs if a strong recurrence-prevention signal is seen.

What separates this program from other MRD strategies in development

Several companies and academic institutions are currently pursuing MRD-targeted strategies using immunotherapy, chemotherapy, or novel antibody–drug conjugates. However, most of those programs still rely on traditional post-relapse intervention or late-line settings. By comparison, TTX-MC138 is positioned not just as an early intervention, but as a molecularly guided therapeutic built explicitly for MRD biology.

This approach places TransCode Therapeutics in a narrow but potentially lucrative category of companies that may define a new class of recurrence-prevention drugs. The product’s reliance on RNA delivery mechanisms and its non-immunogenic nature may also make it attractive for combination use in patients who are not eligible for immunotherapy or who have previously relapsed on standard regimens.

Industry observers also note that while DNA and protein targets dominate most current MRD programs, microRNA modulation remains underexplored and underleveraged despite extensive preclinical validation. If successful, TTX-MC138 could validate this modality and trigger renewed interest in non-coding RNA as a druggable space in oncology.

Where trial success will hinge: biological validation or clinical risk?

Despite the novelty and strategic positioning of the trial, several risks remain. The most immediate challenge is whether ctDNA positivity will translate into measurable recurrence reduction when treated with miR-10b inhibition. While ctDNA has prognostic value, its predictive utility—especially as a trigger for targeted intervention—is still under investigation.

There are also scientific questions around the durability of miR-10b suppression and whether such modulation can meaningfully alter the course of metastatic cascade in vivo. Unlike solid tumor shrinkage, MRD interventions typically require longer follow-up periods and larger datasets to show efficacy, raising the potential for slower-than-expected readouts or ambiguous outcomes.

From a technical standpoint, the delivery mechanism for TTX-MC138 will need to demonstrate consistency in biodistribution and intracellular uptake, particularly in micrometastatic niches. Any signal attenuation in these environments could limit the drug’s ability to eradicate residual disease despite successful systemic administration.

Finally, the scalability of manufacturing for a specialized RNA-based therapeutic may pose challenges if the drug proceeds to later-stage development. Supply chain readiness, cost-of-goods, and GMP compliance for lipid nanoparticle or oligonucleotide-based delivery platforms are still developing areas in the commercial RNA therapeutics landscape.

What broader industry signals this collaboration sends

For stakeholders tracking innovation in recurrence prevention, this collaboration signals a potential turning point. It suggests that both industry and academic sponsors are willing to push RNA therapeutics into more complex clinical settings, including those involving real-world biomarkers, molecular risk stratification, and platform-based validation.

It also highlights the increasing role of nonprofit-led, trial network–driven approaches in drug development, especially for early-phase testing where agility, speed, and infrastructure are key bottlenecks. Quantum Leap’s role in shaping this new MRD-focused protocol may encourage other therapeutic developers to consider similar trial structures when targeting difficult-to-measure outcomes like recurrence.

More broadly, the move positions TransCode Therapeutics as a serious contender in the next wave of precision oncology innovation, where the focus is no longer limited to controlling late-stage tumors, but on preemptively disabling their reemergence at the molecular level.

  colorectal cancer, ctDNA, I-SPY trials, metastasis prevention, microRNA-10b, MRD, Quantum Leap Healthcare Collaborative, RNA therapeutics, TransCode Therapeutics, TTX-MC138